BACKGROUND: Dopamine levels in the prefrontal cortex (PFC) are thought to play an important role in cognitive function and nicotine dependence. The catechol-O-methyltransferase (COMT) inhibitor tolcapone, an FDA-approved treatment for Parkinson's disease, increases prefrontal dopamine levels, with cognitive benefits that may vary by COMT genotype. We tested whether tolcapone alters working memory-related brain activity and performance in abstinent smokers. METHODS: In this double-blind crossover study, 20 smokers completed 8 days of treatment withtolcapone and placebo. In both medication periods, smokers completed blood oxygen level-dependent (BOLD) fMRI scans while performing a working memory N-back task after 24h of abstinence. Smokers were genotyped prospectively for the COMT val(158)met polymorphism for exploratory analysis. RESULTS: Compared to placebo, tolcapone modestly improved accuracy (p=0.017) and enhanced suppression of activation in the ventromedial prefrontal cortex (vmPFC) (p=0.002). There were no effects of medication in other a priori regions of interest (dorsolateral PFC, dorsal cingulate/medial prefrontal cortex, or posterior cingulate cortex). Exploratory analyses suggested that tolcapone led to a decrease in BOLD signal in several regions among smokers with val/val genotypes, but increased or remained unchanged among met allele carriers. Tolcapone did not attenuate craving, mood, or withdrawal symptoms compared to placebo. CONCLUSIONS: Data from this proof-of-concept study do not provide strong support for further evaluation of COMT inhibitors as smoking cessation aids.
RCT Entities:
BACKGROUND:Dopamine levels in the prefrontal cortex (PFC) are thought to play an important role in cognitive function and nicotine dependence. The catechol-O-methyltransferase (COMT) inhibitor tolcapone, an FDA-approved treatment for Parkinson's disease, increases prefrontal dopamine levels, with cognitive benefits that may vary by COMT genotype. We tested whether tolcapone alters working memory-related brain activity and performance in abstinent smokers. METHODS: In this double-blind crossover study, 20 smokers completed 8 days of treatment with tolcapone and placebo. In both medication periods, smokers completed blood oxygen level-dependent (BOLD) fMRI scans while performing a working memory N-back task after 24h of abstinence. Smokers were genotyped prospectively for the COMTval(158)met polymorphism for exploratory analysis. RESULTS: Compared to placebo, tolcapone modestly improved accuracy (p=0.017) and enhanced suppression of activation in the ventromedial prefrontal cortex (vmPFC) (p=0.002). There were no effects of medication in other a priori regions of interest (dorsolateral PFC, dorsal cingulate/medial prefrontal cortex, or posterior cingulate cortex). Exploratory analyses suggested that tolcapone led to a decrease in BOLD signal in several regions among smokers with val/val genotypes, but increased or remained unchanged among met allele carriers. Tolcapone did not attenuate craving, mood, or withdrawal symptoms compared to placebo. CONCLUSIONS: Data from this proof-of-concept study do not provide strong support for further evaluation of COMT inhibitors as smoking cessation aids.
Authors: Susan Colilla; Caryn Lerman; Peter G Shields; Christopher Jepson; Margaret Rukstalis; Jesse Berlin; Angela DeMichele; Greta Bunin; Brian L Strom; Timothy R Rebbeck Journal: Pharmacogenet Genomics Date: 2005-06 Impact factor: 2.089
Authors: Mary Falcone; E Paul Wileyto; Kosha Ruparel; Raphael T Gerraty; Leah LaPrate; John A Detre; Ruben Gur; James Loughead; Caryn Lerman Journal: Addict Biol Date: 2013-03-18 Impact factor: 4.280
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: James Loughead; E Paul Wileyto; Kosha Ruparel; Mary Falcone; Ryan Hopson; Ruben Gur; Caryn Lerman Journal: Neuropsychopharmacology Date: 2014-12-03 Impact factor: 7.853
Authors: Joseph P Schacht; Michaela Hoffman; Konstantin E Voronin; Sarah W Book; Raymond F Anton Journal: Neuropsychopharmacology Date: 2022-05-06 Impact factor: 8.294
Authors: Jon E Grant; Roxanne Hook; Stephanie Valle; Eve Chesivoir; Samuel R Chamberlain Journal: Int Clin Psychopharmacol Date: 2021-09-01 Impact factor: 2.023